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Abstract
Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia
(CLL) in the era of novel agents. However, its effectiveness in the second-line setting—in relation to previous rituximab exposure
in first-line—has hardly been evaluated in a population-based setting. Therefore, in this comprehensive, population-based study,
we assessed the impact of first-line treatment with rituximab-containing chemotherapy on the effectiveness of second-line
treatment with rituximab-containing chemotherapy. We selected all 1735 patients diagnosed with CLL between 2004 and
2010 from the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). The primary endpoint
was treatment-free survival (TFS). First- and second-line treatment was instituted in 663 (38%) and 284 (43%) patients, respec-
tively. In first line, the median TFS was 19.7 and 67.1 months for chemotherapy without (n = 445; 67%) and with rituximab (n =
218; 33%), respectively (adjusted hazard ratio [HRadjusted], 0.83; P = 0.031). The median TFS among recipients of second-line
chemotherapy without (n = 165; 57%) and with rituximab (n = 121; 42%) was 15.0 and 15.3 months, respectively (HRadjusted,
0.93; P = 0.614). Of the 121 patients who received rituximab-containing chemotherapy in second-line, 89 (74%) and 32 (26%)
received first-line chemotherapy without and with rituximab, respectively. Median TFS in these two treatment groups was 18.3
and 12.1 months, respectively (HRadjusted, 1.71; P = 0.060). Collectively, in this population-based study, the effectiveness of first-
line treatment with rituximab-containing chemotherapy was less pronounced in second-line treatment. The hampered effective-
ness of rituximab-containing chemotherapy in second-line could not be explained by previous rituximab exposure.
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Chronic lymphocytic leukemia (CLL) is the most common
leukemia diagnosed in adults, with an overall age-
standardized incidence rate of 4 to 5 per 100,000 persons in
Western countries [1, 2]. Over the past decades, significant
advances have been made in the management of CLL, includ-
ing the advent of purine analogs, chemoimmunotherapy, and,
more recently, kinase inhibitors and anti-apoptotic agents
[3–7]. Despite these advances, most patients with CLL will
ultimately relapse after first-line therapy, highlighting the need
for effective second-line therapy [8]. The management of CLL
in the second-line setting is highly challenging since it has not
been studied in all patient subsets in randomized clinical trials
[9]. Patient- and disease-specific characteristics that guide the
choice of second-line therapy include age, performance status,
comorbidities, genetic aberrations (e.g., TP53 mutation), and
duration of response to first-line chemoimmunotherapy thera-
py [9–13].
Recently, two phase 3 trials reported the superiority of
ibrutinib over chemoimmunotherapy in patients with untreat-
ed CLL, with respect to progression-free survival (PFS) but
not concerning overall survival (OS) [14, 15]. However, the
advantage of ibrutinib in first-line was not clear for mutated
patients. Also, a phase 3 trial demonstrated profound PFS
advantages wi th vene toc lax-obinutuzumab over
chlorambucil-obinutuzumab in previously untreated CLL pa-
tients [16]. Furthermore, in relapsed CLL patients, rituximab-
venetoclax was shown to be more effective, as compared with
chemoimmunotherapy [17]. Thus, it is reasonable to assume
that these novel strategies will make their way into clinical
practice across various lines of CLL treatment. In resource-
limited countries, however, the application of novel agents in
first and subsequent lines of treatment will be carefully
weighed against alternative treatment options due to the sub-
stantial financial burden posed by these novel agents [18].
Against this background, rituximab-containing chemotherapy
is a well-established first-line treatment for patients with CLL
that still holds value, especially among the mutated patients
and patients managed in resource-limited countries [7, 19, 20].
As for second-line treatment, one of the recommendations
in current guidelines is to institute the same type of
chemoimmunotherapy that was applied in first-line when the
interval between the first remission and the need for second-
line therapy exceeds 24 to 36 months [10, 12, 13]. That rec-
ommendation is largely based on findings from the REACH
trial that demonstrated improved outcomes of fludarabine and
cyclophosphamide (FC) with rituximab (FCR), as compared
to FC alone, among previously treated patients with CLL. Of
note, previous therapy with rituximab was an exclusion crite-
rion in the REACH trial [21]. Therefore, the study population
of that trial, which accrued patients between 2003 and 2007,
may not entirely represent the current population of patients
with CLL in need for second-line treatment, since these pa-
tients nowadays typically receive rituximab-containing che-
motherapy in first-line [22, 23].
Recently, we and others have demonstrated the effective-
ness of rituximab added to first-line chemotherapy, as com-
pared to first-line chemotherapy without rituximab, in a
population-based cohort of patients with CLL [22, 23]. In
addition, we were the first to extend these observations by
providing clues about the possible hampered effectiveness of
rituximab added to subsequent lines of chemotherapy. We
suggested that this finding could, in part, be attributed to the
acquisition of rituximab resistance due to prior rituximab ex-
posure. Indeed, several pre-clinical lymphoma studies have
brought forward various mechanisms of acquired rituximab
resistance. [24–26]. However, the small number of patients
receiving subsequent treatment in our previous single-center
study (n = 58) made it difficult to draw firm conclusions
concerning this hypothesis in CLL [22].
Therefore, in this comprehensive population-based study,
covering many hospitals within well-defined geographic re-
gions in the Netherlands, we set out to assess the effectiveness
of rituximab-containing chemotherapy, as compared to che-
motherapy without rituximab, in first- and second-line CLL
treatment.Moreover, emphasis was put to assess whether first-
line treatment with rituximab affected the effectiveness of
second-line treatment with rituximab-based regimens.
Methods
Registries and study population
Established in 1989, the nationwide population-based
Netherlands Cancer Registry (NCR), which is managed by
the Netherlands Comprehensive Cancer Organisation
(IKNL), has an overall nationwide coverage of at least 95%
of all malignancies in the Netherlands [27]. The NCR relies on
comprehensive case notification of all newly diagnosed ma-
lignancies in the Netherlands via the Nationwide Network of
Histopathology and Cytopathology, and the National Registry
of Hospital Discharges (i.e., inpatient and outpatient
discharges).
Trained registrars of the NCR routinely collect basic details
on dates of birth and diagnosis, sex, hospital of diagnosis and
treatment, disease topography and morphology, and primary
treatment started within 12 months after diagnosis through
retrospective medical records review. The date of last known
vital status (i.e., alive, dead, or emigration) is retrieved by
linking the NCR to the Nationwide Population Registries
Network that holds vital statistics of all residents in the
Netherlands.
Although the basic details recorded in the NCR are
essential for national cancer surveillance activities, they
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are insufficient to address more specific questions regard-
ing the delivery of care to patients with CLL. Therefore,
the Dutch Population-based HAematological Registry for
Observational Studies (PHAROS) in CLL—the PHAROS
CLL registry—was established to document additional de-
tails on various patient-, disease-, and treatment-related
characteristics next to the basic details recorded in the
NCR. The more detailed PHAROS CLL registry holds
information about all patients diagnosed with CLL
between January 1, 2004 and December 31, 2010 who
were diagnosed in well-defined geographic regions
that form the Western and Southern part of the
Netherlands (~ 45% of the Dutch population). The
PHAROS CLL registry is conceptually similar to the
PHAROS registry in myelodysplastic syndromes [28].
Details about the NCR and the PHAROS registry,
and their validity, logistics, and completeness were previ-
ously reported [1, 27–29]. Of note, both registries
exclusively include CLL cases that were confirmed by
the physician through bone marrow examination and/or
immunophenotyping of the peripheral blood and/or bone
marrow and classified according to the 2001 criteria of the
World Health Organisation [30].
According to the Central Committee on Research in-
volving Human Subjects (CCMO), this type of observa-
tional, non-interventional study does not require approval
from an ethics committee in the Netherlands. The Privacy
Review Board of the NCR approved the use of anony-
mous data for this study. Informed consent was obtained
from all patients for being included in this study.
Treatment
Patients with CLL who received first- or second-line treat-
ment were categorized into two groups, namely (i) pa-
tients who received rituximab-containing chemotherapy
(+R) or (ii) chemotherapy without rituximab (NoR).
Furthermore, patients who received second-line treatment
with rituximab-containing regimens were categorized into
those who received first-line chemotherapy with (+R/+R)
or without rituximab (NoR/+R). Collectively, our study
encompasses three treatment cohorts. Of note, treatment
with rituximab monotherapy (n = 11) and the application
of rituximab-containing therapy specifically for the treat-
ment of auto-immune complications (n = 13), such as au-
toimmune cytopenia, were excluded from all analyses.
The specific chemotherapeutic backbone, with or without
rituximab, was categorized into purine analogs (i.e..
fludarabine with or without cyclophosphamide), alkylating
agents (i.e., chlorambucil monotherapy or cyclophosphamide
with or without vincristine and prednisone), or other, less
common regimens.
Endpoints
The primary endpoint was treatment-free survival (TFS),
calculated from the start date of treatment until the insti-
tution of subsequent treatment or death [23, 31]. Patients
who were alive in whom subsequent treatment was not
started were censored at the date of last follow-up (i.e.,
December 31, 2014).
The secondary endpoints included time to next treatment
(TTNT), best response, and OS. TTNT was calculated from
the stop of first-line treatment until institution of second-line
treatment or, in case of no subsequent therapy, the date of the
last follow-up. The best response was determined by physi-
cians’ assessment following the guidelines that were valid at
the time [13, 32]. The overall response rate (ORR) was calcu-
lated by adding the proportion of patients who achieved a
complete response (CR) and partial response (PR). OS was
calculated from the start date of treatment until death resulting
from any cause. If death did not occur, patients were censored
at the last of the last follow-up (i.e., December 31, 2014).
Of note, for the group of patients who underwent second-
line treatment, TFS and OS were calculated from the start date
of second-line treatment. Also, TTNTwas calculated from the
stop of second-line treatment until institution of third-line
treatment, or in case of no third-line treatment, the date of
the last follow-up.
Statistical analysis
Baseline characteristics were presented at the time of treat-
ment according to the two treatment groups, stratified by the
three treatment cohorts. The Fisher’s exact test was used to
compare categorical variables and the Kruskal-Wallis test for
continuous variables.
The Kaplan-Meier methodwas used for time-to-event anal-
yses and the log-rank test to compare survival distributions in
a univariable fashion. Multivariable Cox proportional hazard
models were constructed to assess TFS and OS, with adjust-
ment for age at the time of treatment, sex, addition of rituxi-
mab to therapy, the chemotherapeutic backbone, receipt of
rituximab in first-line (only application for analyses in sec-
ond-line), type of therapeutic backbone in first-line (only ap-
plicable for analyses in second-line), and time to next treat-
ment (TTNT; only applicable for analyses in second-line),
unless stated differently. Results from the multivariable
models produce hazard ratios (HRs) with 95% confidence
intervals (CIs). The proportional hazard assumption was test-
ed based on Schoenfeld residuals [33].
All statistical analyses were performed two-sided with a
significance level of 5% (i.e., a P value of 0.05) using






The PHAROS CLL registry includes 1735 adult (≥
18 years) patients diagnosed with CLL between January
1, 2004 and December 31, 2010, with follow-up through
December 31, 2014. For the current study, we selected
663 (38%) patients who initiated first-line treatment, of
whom 445 (67%) and 218 (33%) without and with ritux-
imab, respectively (Supplemental Fig. 1). Baseline char-
acteristics of patients according to the three treatment co-
horts are shown in Table 1. Overall, the median follow-
up—calculated from the start of first-line treatment until
death or last of follow-up, whichever occurred first—for
the entire population was 28 months (range, 0–
121 months). Cytogenetics was performed in a minority
of the patient population at the time of diagnosis.
Patients in the +R group were significantly younger
than those in the NoR group (median age, 66 versus
72 years; P < 0.001). Also, the chemotherapeutic back-
bone was different across the two treatment groups.
Nevertheless, the majority of patients in both treatment
groups were primarily treated with a backbone of
alkylating agents (87% and 58% in the NoR and +R
group, respectively), followed by purine analogs (10%
and 26% in the NoR and +R group, respectively). The
remaining patients received a variety of chemotherapeutic
backbones, of whom in the +R group more often received
such treatment modalities (16%) than those in the NoR
group (3%). The specification of these other, less common
chemotherapeutic backbones across the three treatment
cohorts is listed in Supplemental Table 1. The distribution
of chemotherapeutic backbones remained comparatively
steady over the years studied (data not shown).
Effectiveness
Consistent with prior observations [22, 23], univariable and
multivariable survival analyses demonstrated that first-line
treatment with rituximab-containing chemotherapy resulted
in significantly better TFS (Fig. 1a and Table 2) and OS
Table 1 Patient and treatment characteristics
First-line treatment Second-line treatment Rituximab-containing therapy
in second-line treatment
NoR (n = 445) +R (n = 218) P NoR (n = 165) +R (n = 121) P NoR/+R (n = 89) +R/+R (n = 32) P
Characteristics No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Male sex 288 (65) 142 (66) 0.794 110 (67) 80 (67) 1.00 58 (66) 22 (71) 0.662
Median age 72 (33–95) 66 (35–93) < 0.001 72 (37–95) 68 (40–92) 0.013 70 (37–88) 67 (40–83) 0.187
18–64 145 (33) 109 (50) < 0.001 51 (31) 56 (46) 0.020 39 (44) 17 (53) 0.260
65–74 154 (35) 79 (26) 0.171 66 (40) 45 (37) 0.504 34 (38) 11 (34) 0.770
≥ 75 146 (33) 30 (14) < 0.001 48 (29) 20 (17) 0.064 16 (18) 4 (13) 0.081
FISH analysis
Deletion 17p 3 (1) 3 (1) 0.370 1 (1) 2 (2) 0.737 1 (1) 1 (3) 0.446
Deletion 11q 5 (1) 6 (3) 0.123 1 (1) 2 (2) 0.737 1 (1) 1 (3) 0.446
Trisomy 12 14 (3) 10 (4) 0.351 5 (3) 7 (6) 0.251 5 (6) 2 (6) 0.896
Deletion 13q 25 (6) 19 (9) 0.132 7 (4) 9 (7) 0.245 5 (6) 4 (13) 0.203
Normal or none
of above
30 (7) 20 (9) 0.676 20 (12) 18 (15) 0.498 15 (17) 3 (9) 0.308
Not performed 329 (74) 143 (66) 0.026 125 (76) 81 (67) 0.101 61 (69) 20 (63) 0.533
Unknown 37 (8) 17 (8) 0.804 6 (4) 2 (2) 0.129 1 (1) 1 (3) 0.094
Chemotherapeutic backbone in first-line
Alkylating agents 389 (87) 127 (58) < 0.001 150 (91) 101 (83) 0.058 77 (87) 24 (75) 0.133
Purine analogs 44 (10) 57 (26) < 0.001 11 (7) 17 (14) 0.038 12 (13) 5 (16) 0.765
Other 12 (3) 34 (16) < 0.001 4 (2) 3 (3) 0.976 0 (0) 3 (9) 0.003
Chemotherapeutic backbone in second-line
Alkylating agents 118 (72) 66 (54) 0.003 56 (63) 10 (31) 0.002
Purine analogs 38 (23) 37 (31) 0.152 23 (25) 14 (44) 0.059
Other 9 (5) 18 (15) 0.007 10 (11) 8 (25) 0.061
Median TTNTa 10 (0–70) 11 (0–63) 0.200 10 (0–97) 10 (0–81) 0.461 12 (0–81) 8 (1–56) 0.260
Median follow-up time 32 (0–121) 25 (0–97) < 0.001 21 (0–97) 36 (0–80) 0.029 19 (0–80) 8 (0–61) < 0.001
NoR chemotherapy without rituximab, +R rituximab-containing chemotherapy, TTNT time to next treatment, FISH fluorescent in situ hybridization
a TTNT was calculated in months from the stop of first-line treatment until institution of second-line treatment. For patients in the second-line cohort,
TTNTwas calculated from stop of second until institution of third-line treatment
Italics denotes P values less than 0.05
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(Fig. 1b and Table 2), as compared to chemotherapy without
rituximab (P for all comparisons < 0.05). Variables associated
with inferior TFS and OS were age per 1-year increase and
male sex (for TFS and OS). In addition, treatment with a
chemotherapeutic backbone including a purine analog or oth-
er, less common chemotherapeutic regimens was associated
with inferior OS. The ORR was higher among recipients of
first-line therapy with rituximab-containing chemotherapy, as
compared to recipients of first-line chemotherapy without ri-
tuximab (79% versus 59%; P < .001).
Second-line treatment
Patient characteristics
Second-line treatment was initiated in 286 (43%) of 663 pa-
tients, of whom 165 (58%) without rituximab and 121 (42%)
with rituximab (Table 1). Similar to the first-line cohort, pa-
tients in the +R group were significantly younger than those in
the NoR group (median age, 68 versus 72 years;P = 0.013). In
addition, most patients in the two treatment groups received
Fig. 1 Treatment-free survival (a) and overall survival (b) among patients with chronic lymphocytic leukemia who received first-line treatment with or
without rituximab
Table 2 Cox regression
analyses for treatment-
free survival and overall
survival in first-line
treatment
Covariate Treatment-free survival Overall survival
HR 95% CI P HR 95% CI P
Age at treatment, yearsª 1.02 1.01 – 1.03 < 0.001 1.06 1.05 – 1.08 < 0.001
Sex
Male 1 ref 1 ref
Female 0.78 0.66 – 0.92 0.004 0.69 0.54 – 0.87 0.002
Receipt of rituximab
No 1 ref 1 ref
Yes 0.83 0.70 – 0.98 0.031 0.72 0.54 – 0.96 0.023
Chemotherapeutic backbone
Alkylating agents 1 1 ref
Purine analogues 0.87 0.69 – 1.09 0.231 1.44 1.00 – 2.06 0.048
Other 1.13 0.83 – 1.54 0.446 2.18 1.44 – 3.31 < 0.001
HR hazard ratio, CI confidence interval
Linear estimate per one-year increase
Italics denotes P values less than 0.05
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second-line treatment with a backbone of alkylating agents
(72% and 54% in the NoR and + R group, respectively).
Interestingly, the vast majority of patients in the two treatment
groups received first-line treatment with a backbone of
alkylating agents (91% and 83% in the NoR and + R group,
respectively).
Effectiveness
Univariable survival analysis showed similar TFS between
second-line treatment with or without rituximab (median
TFS, 15.3 versus 15.0 months; P for log-rank = 0.318;
Fig. 2a). In multivariable analysis, the adjusted HR was not
statistically significant different between the two treatment
groups (HR, 0.93; 95% CI, 0.70–1.23; P = 0.614; Table 3).
Predictors associated with poorer TFS included age per 1-year
increase and first-line therapy with a backbone of purine ana-
logs, as compared with a backbone of alkylating agents
(Table 3). Conversely, patients who had a longer TTNT had
better TFS (HR per 1-month increase, 0.98; 95% CI, 0.96–
0.99; P < 0.001; Table 3).
Similar to TFS, the median OS (Fig. 2b) and the adjusted
risk of death (Table 3) were not statistically significant different
between the two treatment groups. Also, the multivariable anal-
ysis revealed associations similar to those for TFS (Table 3). In
addition, patients who received second-line therapy with a ther-
apeutic backbone other than the commonly applied backbones
(i.e., alkylating agents and purine analogs) had a higher adjust-
ed risk of death compared to patients who received second-line
therapy with a backbone of alkylating agents (Table 3).
No differences with respect to the ORR were found be-
tween recipients of second-line therapy with or without ritux-
imab (56% versus 52%; P = 0.746).
Rituximab-containing therapy in second-line
Patient characteristics
Next, we specifically focused on 121 patients who received
rituximab-containing therapy in second-line. Of these pa-
tients, 32 (26%; +R/+R) and 89 (74%; NoR/+R) received
first-line therapy with and without rituximab, respectively
(Table 1). Of note, patients in the +R/+R group received pu-
rine analog-based chemotherapy more frequently, as com-
pared to the NoR group (44% versus 25%; P < 0.001).
Furthermore, 98 (34%) recipients of second-line therapy re-
ceived the same chemotherapeutic backbone as was applied in
first-line, namely alkylating agents (n = 96), purine analog
(n = 1) and cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP; n = 1).
Effectiveness
Univariable survival analysis showed similar TFS between
patients in the NoR/+R and +R/+R group (median TFS,
18.3 months versus 12.1 months; P for log-rank = 0.243;
Fig. 3a). In multivariable analysis, the adjusted HR was not
statistically significant different between the two treatment
groups (HR, 1.71; 95% CI, 0.98–2.96; P = 0.060; Table 4).
First-line treatment with a backbone of purine analogs, as
Fig. 2 Treatment-free survival (a) and overall survival (b) among patients with chronic lymphocytic leukemia who received second-line treatment with
or without rituximab
Ann Hematol
compared with alkylating agents, was associated with a poorer
TFS (HR, 2.62; 95% CI, 1.26–5.52, P = 0.010; Table 4),
whereas patients with a longer TTNT had better TFS (HR
per 1-month increase, 0.97; 95% CI 0.96–0.97; P = 0.003;
Table 4).
Similar to TFS, the median OS (Fig. 3b) and the adjusted
risk of death (Table 4) were not statistically significant different
between the NoR/+R and +R/+R groups. In addition, in multi-
variable analysis, age per 1-year increase (HR 1.04; 95% CI,
1.01–1.07;P= 0.009) was associatedwith inferior OS, whereas
a shorter TTNT (HR per 1-month increase, 0.98; 95%CI, 0.95–
1.00; P= 0.042) was associated with better OS (Table 4).
No differences with respect to the ORR were found be-
tween recipients of second-line therapy with or without ritux-
imab (50% versus 60%; P = 1.00).
Of note, exploratory analysis to assess TFS and OS in
patients who were never treated with rituximab in first- and
second-line (termed as the ‘NoR/NoR group’) showed no dif-
ference in outcome, as compared with the NoR/+R and +R/+R
groups (Supplemental Table 2 and Supplemental Fig. 2).
Discussion
In this population-based study, we assessed the effectiveness
of rituximab added to first- and second-line chemotherapy in
CLL—with special emphasis whether the effectiveness of
rituximab-containing therapy in second-line is affected by ri-
tuximab therapy in first-line. This emphasis was put on be-
cause chemoimmunotherapy is still regularly used in many
countries across the globe in first- and second-line treatment.
To our knowledge, this is the first population-based study that
assessed the latter and more comprehensively assessed the
former.
Congruent with findings from phase 3 trials [7, 19, 20], we
demonstrated that the combination of rituximab to first-line
chemotherapy—as compared to chemotherapy without
rituximab—improved TFS, OS, and ORRs in patients with
CLL within a population-based setting. Recently, two
population-based studies demonstrated similar findings.
However, one study only included patients managed within
one region [23], whereas the other study only included pa-
tients managed within a single center [22]. Therefore, the
present population-based study is the first that assessed the
effectiveness of rituximab-containing therapy across several
geographic regions encompassing multiple hospitals.
Collectively, mainly owing to its relatively short-course of
administration and cost-effective profile, first-line
chemoimmunotherapy remains a viable treatment option in
resource-limited countries and for the great majority of pa-
tients without adverse genetic factors such as TP53 aberra-
tions, especially in mutated patients.
Table 3 Cox regression analyses for treatment-free survival and overall survival in second-line treatment
Covariate Treatment-free survival Overall survival
HR 95% CI P HR 95% CI P
Age at treatment, yearsa 1.02 1.00 – 1.04 0.013 1.05 1.04 – 1.07 < 0.001
Sex
Male 1 ref 1 ref
Female 0.98 0.74 – 1.31 0.880 0.74 0.53 – 1.05 0.096
Receipt of second-line rituximab
No 1 ref 1 ref
Yes 0.93 0.70 – 1.23 0.614 0.99 0.70 – 1.39 0.934
Chemotherapeutic backbone in first-line
Alkylating agents 1 ref 1 ref
Purine analogs 1.95 1.24 – 3.06 0.004 2.50 1.46 – 4.29 0.001
Other 0.95 0.38 – 2.34 0.906 1.41 0.51 – 3.91 0.505
Chemotherapeutic backbone in second-line
Alkylating agents 1 ref 1 ref
Purine analogs 0.84 0.61 – 1.15 0.269 1.12 0.77 – 1.63 0.550
Other 1.51 0.93 – 2.45 0.099 2.12 1.23 – 3.65 0.007
TTNTb 0.98 0.96 – 0.99 < 0.001 0.97 0.96 – 0.99 0.001
HR hazard ratio, CI confidence interval, TTNT time to next treatment
a Linear estimate per 1-year increase
b Linear estimate per 1-month increase
Italics denotes P values less than 0.05
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In contrast to the effectiveness of rituximab-containing
therapy in first-line CLL treatment, an apparent lack of
effectiveness of rituximab added to second-line chemotherapy
was objectivated. Nevertheless, our finding contradicts that
of the REACH trial [21] that demonstrated the efficacy of
FCR, as compared to FC, among patients with CLL in the
Table 4 Cox regression analyses
for treatment-free survival and




Covariate Treatment-free survival Overall survival
HR 95% CI P HR 95% CI P
Age at treatment, yearsa 1.01 0.99 – 1.04 0.352 1.04 1.01 – 1.07 0.009
Sex
Male 1 ref 1 ref
Female 0.91 0.57 – 1.46 0.705 0.83 0.47 – 1.45 0.511
Receipt of first-line rituximab
No 1 ref 1 ref
Yes 1.71 0.98 – 2.96 0.060 1.09 0.54 – 2.20 0.818
Chemotherapeutic backbone in first-line
Alkylating agents 1 ref 1 ref
Purine analogs 2.62 1.26 – 5.42 0.010 2.34 0.96 – 5.68 0.061
Other 0.55 0.07 – 4.38 0.571 1.84 0.22 – 15.7 0.578
Chemotherapeutic backbone in second-line
Alkylating agents 1 ref 1 ref
Purine analogs 0.83 0.50 – 1.39 0.487 1.06 0.56 – 2.01 0.852
Other 1.33 0.66 – 2.67 0.420 1.80 0.78 – 4.12 0.166
TTNTb 0.97 0.95 – 0.99 0.003 0.98 0.95 – 1.00 0.042
HR hazard ratio, CI confidence interval, TTNT time to next treatment
a Linear estimate per 1-year increase
b Linear estimate per 1-month increase
Italics denotes P values less than 0.05
Fig. 3 Treatment-free survival (a) and overall survival (b) among patients with chronic lymphocytic leukemia who received rituximab-containing
therapy in second-line according to the receipt of first-line therapy with or without rituximab
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relapsed/refractory setting. Several arguments can be brought
forward to explain the differences between our study and
the REACH trial. As in most randomized controlled trials,
the median age of patients is lower (e.g., 62 years in the
REACH trial versus 72 years in this study) and patients
generally have more favorable Eastern Cooperative
OncologyGroup (ECOG) performance scores and less serious
comorbidities, as compared to patients managed in routine
clinical practice. Furthermore, patients were not eligible for
inclusion in the REACH trial when they were previously treat-
ed with rituximab. Thus, the exclusion of these patients results
in selection bias. Although we demonstrated that second-line
treatment with rituximab was comparable for patients with
and without prior rituximab exposure, findings of the
REACH trial cannot be extrapolated to a contemporary CLL
population. Patients with CLL in the relapsed/refractory
setting have often been treated with rituximab-based
chemotherapy in first-line as part of standard care in contem-
porary clinical practices.
Very recently, the combination of venetoclax-rituximab
was shown to be more effective in second-line treatment in
terms of PFS [17]. However, considering the risk of tumor
lysis syndrome, this combination is preferably not applied in
patients with impaired kidney function. Furthermore, the du-
ration of treatment with novel combinations, such as
venetoclax-rituximab, is considerably longer, as compared to
chemoimmunotherapy, which could lead to premature treat-
ment discontinuation due to patient discouragement. Lastly,
the market uptake of venetoclax (and ibrutinib) might be ham-
pered in resource-limited countries [18]. As a result, the posi-
tion of novel combinations in the treatment algorithm of CLL
is continuously being debated. Taken collectively,
chemoimmunotherapy is a viable option that still might be
routinely applied in second-line treatment.
The hypothesis about the reduced effectiveness of rituxi-
mab in second-line treatment is deduced from the hypothesis
of acquired rituximab resistance in non-Hodgkin lymphomas
[34]. At present, only one study (that is, the prospective non-
interventional PERLE study) specifically described the man-
agement of relapsed/refractory patients with CLL previously
treated with rituximab in first-line and retreated with a
rituximab-based regimen [35]. However, that study did not
report on survival outcomes. We demonstrated that the effec-
tiveness of second-line treatment with rituximab-containing
regimens was not influenced by the application of rituximab
in first-line. More specifically, these patients demonstrated
TFS, OS, and ORR similar to those who received second-
line therapy with rituximab-containing regimens without
treatment with rituximab in first-line. Therefore, the hypothe-
sis of acquired rituximab resistance could not be confirmed by
the current study.
We certainly acknowledge that the comparatively low
number of patients who received rituximab-containing
therapy in both first- and second-line (n = 31) might have
prevented to reveal a statistically significant difference be-
tween the NoR/+R and +R/+R groups. Furthermore, in a
population-based setting, the choice of a particular
treatment strategy is mainly influenced by the physician
(i.e., confounding by indication). Therefore, the addition
of rituximab to chemotherapy or the application of a more
intensive chemotherapeutic backbone may reflect a height-
ened sense of urgency of response, thereby leading to
variability regarding the initiation of a particular treatment.
In addition, second-line treatment with rituximab in combi-
nation with alkylating agents appeared to be more often
applied in the NoR/+R group (63% versus 31% in the
+R/+R group). This might suggest that patients in the
+R/+R group received a chemotherapeutic backbone in
second-line with higher effectiveness (i.e., purine analogs
and CHOP) that might counteract or conceal the resistance
to rituximab. Therefore, it would be worthwhile to address
the hypothesis regarding acquired rituximab resistance in a
larger, broader population-based cohort of patients with
CLL who received second-line treatment. Such an analysis
will allow studying the effectiveness of specific types of
rituximab-containing therapy in second-line while
considering prior treatment with rituximab in first-line.
The strength of our study includes the use of a population-
based cancer registry with comprehensive data available for
individual patients. Furthermore, this is the first population-
based study that provides comprehensive information on the
effectiveness of second-line rituximab-based treatment with
and without prior rituximab exposure. Limitations of our
study mainly pertain to the lack of clinical information regard-
ing the patient’s fitness and response assessment (i.e., infor-
mation on CT scans and bone marrow examination).
Furthermore, since cytogenetic analysis was solely performed
at diagnosis and not performed in a large number of patients,
we were unable to include these well-known prognostic
factors into the multivariable model.
In conclusion, in this population-based study, rituximab-
containing therapy, as compared to therapy without rituximab,
improves outcomes in patients with CLL in the front-line set-
ting. However, the effectiveness of rituximab-containing ther-
apy in second-line seems to be equal to that of second-line
therapy without rituximab. Furthermore, its effectiveness
seems not to be influenced by prior treatment with rituximab
in first-line. Future population-based research is imperative to
assess whether novel strategies, such as ibrutinib or rituximab
with venetoclax, may improve outcomes among patients with
CLL in the relapsed/refractory setting. In the meantime, while
we await larger, broader population-based studies that address
the effectiveness of rituximab-containing therapy in second-
line CLL treatment, standard chemoimmunotherapy,
ibrutinib, or rituximab and venetoclax remains the standard
of care for second-line CLL treatment.
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Acknowledgments The Population-based HAematological Registry for
Observational Studies (PHAROS) is an initiative of the Haemato-
Oncology Foundation for Adults in The Netherlands (HOVON), the
institute of Medical Technology Assessment (iMTA) at the Erasmus
University Rotterdam, and the Netherlands Comprehensive Cancer
Organisation (IKNL). We are grateful to all participating centers, hema-
tologists, research nurses, and data managers for their contributions and
efforts that allowed for additional data collection.
Authors’ contributions LvdS, AGD, and M-DL designed the study;
LvdS analyzed the data; AGD provided statistical support; ECvdB col-
lected the data; LvdS wrote the manuscript with contributions from all
authors, who also interpreted the data, and read, commented on, and
approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
References
1. Van den Broek E, Kater A, van de Schans S, Karim-Kos H,
Janssen-Heijnen M, Peters W et al (2012) Chronic lymphocytic
leukaemia in the Netherlands: trends in incidence, treatment and
survival, 1989–2008. Eur J Cancer 48(6):889–895
2. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N,
Björkholm M, Landgren O (2009) Improved survival in chronic
lymphocytic leukemia in the past decade: a population-based study
including 11,179 patients diagnosed between 1973–2003 in
Sweden. haematologica. 94(9):1259–1265
3. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD,
Gerecitano JF et al (2016) Targeting BCL2 with venetoclax in
relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):
311–322
4. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey
O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux
S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z,
Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M,
Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D,
Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2
Investigators (2015) Ibrutinib as initial therapy for patients with
chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437
5. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM,
Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P,
Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S,
Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li
D, Jahn TM, Dansey RD, Hallek M, O'Brien SM (2014) Idelalisib
and rituximab in relapsed chronic lymphocytic leukemia. N Engl J
Med 370(11):997–1007
6. Hallek M (2017) Chronic lymphocytic leukemia: 2017 update on
diagnosis, risk stratification, and treatment. Am J Hematol 92(9):
946–965
7. HallekM, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer
J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann
M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF,
Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A,
Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz
T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H,
Stilgenbauer S, International Group of Investigators, German
Chronic Lymphocytic Leukaemia Study Group (2010) Addition
of rituximab to fludarabine and cyclophosphamide in patients with
chronic lymphocytic leukaemia: a randomised, open-label, phase 3
trial. Lancet. 376(9747):1164–1174
8. Delgado J, Baumann T, Ghita G, Montserrat E (2012) Chronic
lymphocytic leukemia therapy: beyond chemoimmunotherapy.
Curr Pharm Des 18(23):3356–3362
9. Shustik C, Bence-Bruckler I, Delage R, Owen CJ, Toze CL, Coutre
S (2017) Advances in the treatment of relapsed/refractory chronic
lymphocytic leukemia. Ann Hematol 96(7):1185–1196
10. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M
et al (2015) Chronic lymphocytic leukaemia: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol 26(suppl_5):v78–v84
11. Smolewski P, Witkowska M, Korycka-Wołowiec A (2013) New
insights into biology, prognostic factors, and current therapeutic
strategies in chronic lymphocytic leukemia. ISRN Oncol 2013:7
12. group DBHCw (2016) Dutch guidelines for the diagnosis and treat-
ment of chronic lymphocytic leukaemia. Neth J Med 74(2):68
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero
G, Döhner H, Hillmen P, KeatingMJ, Montserrat E, Rai KR, Kipps
TJ, International Workshop on Chronic Lymphocytic Leukemia
(2008) Guidelines for the diagnosis and treatment of chronic lym-
phocytic leukemia: a report from the International Workshop on
Chronic Lymphocytic Leukemia updating the National Cancer
Institute–working group 1996 guidelines. Blood. 111(12):5446–
5456
14. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding
W et al (2018) Ibrutinib regimens versus chemoimmunotherapy in
older patients with untreated CLL. N Engl J Med 379(26):2517–
2528
15. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L,
Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V,
Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF,
Styles L, Flinn IW (2019) Ibrutinib plus obinutuzumab versus
chlorambucil plus obinutuzumab in first-line treatment of chronic
lymphocytic leukaemia (iLLUMINATE): a multicentre,
randomised, open-label, phase 3 trial. Lancet Oncol 20(1):43–56
16. Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M
et al (2019) Venetoclax and obinutuzumab in patients with CLL and
coexisting conditions. N Engl J Med 380(23):2225–2236
17. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids
MS et al (2017) Venetoclax plus rituximab in relapsed or refractory
chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol
18(2):230–240
18. Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, DingW, Leis JF
et al (2015) Impact of ibrutinib and idelalisib on the pharmaceutical
cost of treating chronic lymphocytic leukemia at the individual and
societal levels. J Oncol Pract 11(3):252–258
19. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner
CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S,
Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H,
Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K,
Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in
patients with CLL and coexisting conditions. N Engl J Med
370(12):1101–1110
20. Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C
et al (2016) First-line chemoimmunotherapy with bendamustine
and rituximab versus fludarabine, cyclophosphamide, and rituxi-
mab in patients with advanced chronic lymphocytic leukaemia
(CLL10): an international, open-label, randomised, phase 3, non-
inferiority trial. The Lancet Oncology 17(7):928–942
21. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K,
Loscertales J, Catalano J et al (2010) Rituximab plus fludarabine
and cyclophosphamide prolongs progression-free survival com-
pared with fludarabine and cyclophosphamide alone in previously
treated chronic lymphocytic leukemia. J Clin Oncol 28(10):1756–
1765
Ann Hematol
22. van der Straten L, Dinmohamed AG, Westerweel PE, Langerak
AW, Riedl J, Doorduijn JK et al (2018) Rituximab addition to
chemotherapy in real world patients with chronic lymphocytic leu-
kemia: effective in first line but indication of lack of efficacy in
subsequent lines of therapy. Leuk Lymphoma 59(11):2757–2761
23. Lee LJ, Toze CL, Huang SJ, Gillan TL, Connors JM, Sehn LH et al
(2018) Improved survival outcomes with the addition of rituximab
to initial therapy for chronic lymphocytic leukemia: a comparative
effectiveness analysis in the province of British Columbia, Canada.
Leuk Lymphoma 59(6):1356–1363
24. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S (2006)
Analysis of changes in CD20, CD55, and CD59 expression on
established rituximab-resistant B-lymphoma cell lines. Leuk Res
30(5):625–631
25. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G-M,
Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic
response of B lymphoma cells to anti-CD20 monoclonal antibody
rituximab in vitro: CD55 andCD59 regulate complement-mediated
cell lysis. Blood. 95(12):3900–3908
26. Marquez ME, Hernández-Uzcátegui O, Cornejo A, Vargas P, Da
Costa O (2015) Bone marrow stromal mesenchymal cells induce
down regulation of CD20 expression on B-CLL: implications for
rituximab resistance in CLL. Br J Haematol 169(2):211–218
27. Schouten LJ, Höppener P, Van den Brandt PA, Knotternus AJ, Jager
JJ (1993) Completeness of cancer registration in Limburg,
The Netherlands. Int J Epidemiol 22(3):369–376
28. Dinmohamed A, van Norden Y, Visser O, Posthuma E, Huijgens P,
Sonneveld P, van de Loosdrecht A, Jongen-Lavrencic M (2015)
Effectiveness of azacitidine for the treatment of higher-risk
myelodysplastic syndromes in daily practice: results from the
Dutch population-based PHAROS MDS registry. Leukemia.
29(12):2449–2451
29. Dinmohamed AG, van Norden Y, Visser O, Posthuma EFM,
Huijgens PC, Sonneveld P, van de Loosdrecht A, Jongen-
Lavrencic M (2015) The use of medical claims to assess incidence,
diagnostic procedures and initial treatment of myelodysplastic syn-
dromes and chronic myelomonocytic leukemia in the Netherlands.
Leuk Res 39(2):177–182
30. Jaffe EHNSH, Vardinman JW (eds) (2001) World Health
Organization classification of tumours: pathology and genetics of
tumours of haematopoietic and lymphoid tissues. AnnOncol 13(3):
490–491
31. Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann
M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs
G, Goede V, FinkAM, Elter T, Fischer K,Wendtner CM, HallekM,
Eichhorst B (2015) Outcome of advanced chronic lymphocytic leu-
kemia following different first-line and relapse therapies: a meta-
analysis of five prospective trials by the German CLL Study Group
(GCLLSG). Haematologica. 100(11):1451–1459
32. Cheson B, Bennett J, Grever M, Kay N, Keating M, O'Brien S et al
(1996) National Cancer Institute-sponsored Working Group guide-
lines for chronic lymphocytic leukemia: revised guidelines for di-
agnosis and treatment. Blood. 87(12):4990–4997
33. Grambsch PM, Therneau TM (1994) Proportional hazards tests and
diagnostics based on weighted residuals. Biometrika. 81(3):515–
526
34. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K,
Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A,
Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson
G, Cheson BD (2016) Obinutuzumab plus bendamustine versus
bendamustine monotherapy in patients with rituximab-refractory
indolent non-Hodgkin lymphoma (GADOLIN): a randomised, con-
trolled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):
1081–1093
35. Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O,
Arkam Y, Orfeuvre H, DilhuydyMS, Barry M, Jourdan E, Dreyfus
B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M,
Delmer A (2017) Relapsed chronic lymphocytic leukemia retreated
with rituximab: interim results of the PERLE study. Leuk
Lymphoma 58(6):1366–1375
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Ann Hematol
